

## Supporting Information

### Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis

Phuong Chi Nguyen<sup>1</sup>, Vincent Delorme<sup>4</sup> #, Anaïs Bénarouche<sup>1</sup>, Benjamin P. Martin<sup>2</sup>, Rishi Paudel<sup>2</sup>, Giri R. Gnawali<sup>2</sup>, Abdeldjalil Madani<sup>1</sup>, Rémy Puppò<sup>3</sup>, Valérie Landry<sup>4</sup>, Laurent Kremer<sup>5,6</sup>, Priscille Brodin<sup>4</sup>, Christopher D. Spilling<sup>2</sup>, Jean-François Cavalier<sup>1\*</sup> and Stéphane Canaan<sup>1\*</sup>

<sup>1</sup> Aix-Marseille Univ, CNRS, EIPL, *IMM FR3479*, Marseille, France

<sup>2</sup> Department of Chemistry and Biochemistry, University of Missouri–St. Louis, One University Boulevard, St. Louis, Missouri 63121, United States

<sup>3</sup> Aix Marseille Univ, CNRS, Institut de Microbiologie de la Méditerranée FR3479, plate-forme Marseille Protéomique (MaP), Marseille, France

<sup>4</sup> INSERM U1019 CNRS-UMR 8204, Institut Pasteur de Lille, Université de Lille, 1 rue du Professeur Calmette, Lille, France

<sup>5</sup> Institut de Recherche en Infectiologie de Montpellier (IRIM), CNRS, UMR 9004, Université de Montpellier


<sup>6</sup> IRIM, INSERM, 34293, Montpellier, France

\* Correspondance: [canaan@imm.cnrs.fr](mailto:canaan@imm.cnrs.fr) (S. Canaan); [jfcavalier@imm.cnrs.fr](mailto:jfcavalier@imm.cnrs.fr) (J.-F. Cavalier)


# *Current Address: Tuberculosis Research Laboratory, Institut Pasteur Korea, Seongnam-si, Gyeonggi-do, 13488 Republic of Korea.*

### Contents


<sup>1</sup> H, <sup>13</sup> C NMR and <sup>31</sup> P NMR spectra of CyC <sub>13(α)</sub> ( <b>Figure S1</b> )	S2
<sup>1</sup> H, <sup>13</sup> C NMR and <sup>31</sup> P NMR spectra of CyC <sub>13(β)</sub> ( <b>Figure S2</b> )	S5
Primers used in this study ( <b>Table S2</b> )	S8
Chemical structures of TAMRA-FP and Desthiobiotin-FP ( <b>Figure S3</b> )	S9
Western blot analysis of <i>M. tb</i> mc <sup>2</sup> 6230 overexpression strains ( <b>Figure S4</b> )	S10




**Figure S1A.** <sup>1</sup>H NMR spectrum of CyC<sub>13</sub>(α) recorded at 300 MHz, and using CDCl<sub>3</sub> (δ = 7.27 ppm) as an internal standard of solvent.




**Figure S1B.**  $^{13}\text{C}$  NMR spectrum of  $\text{CyC}_{13}(\alpha)$  recorded at 75 MHz, and using  $\text{CDCl}_3$  ( $\delta = 77.23$  ppm) as an internal standard of solvent.




**Figure S1C.** <sup>31</sup>P NMR spectrum of **CyC<sub>13</sub>( $\alpha$ )** recorded at 121 MHz and referenced to external 85% H<sub>3</sub>PO<sub>4</sub> (0 ppm).



**Figure S2A.** <sup>1</sup>H NMR spectrum of **CyC<sub>13</sub>(β)** recorded at 300 MHz, and using CDCl<sub>3</sub> (δ = 7.27 ppm) as an internal standard of solvent.



**Figure S2B.** <sup>13</sup>C NMR spectrum of CyC<sub>13</sub>(β) recorded at 75 MHz, and using CDCl<sub>3</sub> (δ = 77.23 ppm) as an internal standard of solvent.




**Figure S2C.**  $^{31}P$  NMR spectrum of **CyC<sub>13</sub>(β)** recorded at 121 MHz and referenced to external 85%  $H_3PO_4$  (0 ppm).


**Table S2.** Primers used in this study. Restriction sites if present are underlined.

Gene	Primer	Sequence (5'-3')	Restriction site
<i>Ag85A-F</i>	Forward	5'-CCCAGCTTGTGACAGGGTTCGTG -3'	
<i>Ag85A-R</i>	Reverse	5'-ACCATGGATCCCTAGGCGCCCTGGGGCGCG-3'	BamHI
<i>Ag85C-F</i>	Forward	5'-CCACGTTCTTCGAACAGGTGCGAAG-3'	
<i>Ag85C-R</i>	Reverse	5'-ACCATGGATCCTCAGGCGGCCGGCGCAGCAG-3'	BamHI
<i>Rv0183-F</i>	Forward	5'-GGAAATCATATGACTACCACCCGGACTG-3'	NdeI
<i>Rv0183-R</i>	Reverse	5'-CGGCGGGATCCCCGACAACCGCTCGGTGAGCC-3'	BamHI
<i>LipH-F</i>	Forward	5'-GGAAATCATATGACAGAGCCGACCGTCG-3'	NdeI
<i>LipH-R</i>	Reverse	5'-CGGCGGGATCCCTGATGCGTGCAACGCCCTCTTC-3'	BamHI
<i>TesA-F</i>	Forward	5'-CCAGCATATGCTGGCCCGTCACGGACCACG-3'	NdeI
<i>TesA-R</i>	Reverse	5'-CCAGAAGCTTAGCTCGATCATGCCATTGGAGTGTT-3'	HindIII
<i>HsaD-F</i>	Forward	5'-CCAGCATATGACAGCTACCGAGGAATTGACGT-3'	NdeI
<i>HsaD-R</i>	Reverse	5'-CCAGAAGCTTTCTGCCACCTCCCAGAAATTCAATC-3'	HindIII





**Figure S3.** Chemical structures of TAMRA-FP for in-gel fluorescence detection and Desthiobiotin-FP for target enrichment. Each probe forms an irreversible covalent bond with an active site serine (or cysteine) for irreversible enzyme labelling.



**Figure S4.** Western blot analysis of *M. tb* mc<sup>2</sup>6230 overexpression strains as described in **Material and Methods** section. Each overexpressed protein is indicated with a red star and compared to the *M. tb* mc<sup>2</sup>6230 wild type strain. Ag85A and Ag85C overexpression strains were revealed using specific monoclonal antibody directed against Ag85 complex; specific anti-Rv0183 rabbit polyclonal antibodies were used in the case of Rv0183 overexpression strain; while the other three overexpressed proteins (*i.e.*, LipH, TesA and HsaD) were revealed by HisProbe-HRP conjugated (Thermo-Fisher Scientific).